Leukemia & lymphoma

publication venue for

Short report: penile lymphoma following local injections for erectile dysfunction. 2001
Near-tetraploidy/tetraploidy acute myeloid leukemia with clinical, pathologic and molecular characteristics. 2024
A case of testicular diffuse large B-cell lymphoma with late relapse in the skin: the critical role of comparative phenotypic, clonality, and cytogenetic testing. 2024
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML). 2024
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression. 2023
Preclinical and clinical evaluation of Buparlisib (BKM120) in recurrent/refractory Central Nervous System Lymphoma.. 64. 2023
Impact of KRAS and NRAS mutations on outcomes in acute myeloid leukemia.. 64. 2023
Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML. 2023
EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. 2023
Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group. 2023
The potential for technology to aid quantitative assessment in cutaneous T cell lymphoma.. 63. 2022
Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndrome. 2022
Patient-reported outcomes of patients with myelofibrosis or essential thrombocythemia enrolled in the MOST study. 2022
A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia. 2022
Impact of omitting post-transplant minidose-methotrexate doses in allogeneic hematopoietic cell transplantation.. 63. 2022
The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma.. 63. 2022
Loss of function mutations of BCOR in classical Hodgkin lymphoma. 2021
Adenovirus viremia after in vivo T-cell depleted allo-transplant in adults: low lymphocyte counts are associated with uncontrolled viremia and fatal outcomes.. 63. 2021
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. 2021
A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia. 2021
Idelalisib immune-related toxicity is associated with improved treatment response. 2021
Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality.. 62. 2021
What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)? 2021
Unmet need for mental health services in indolent lymphoma: age differences over one-year post-diagnosis.. 62. 2021
Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience.. 62. 2021
Evaluation of the prognostic utility of bone marrow biopsy in diffuse large B-Cell lymphoma in the SEER-Medicare dataset.. 62. 2021
A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome.. 62. 2021
Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma.. 62. 2021
Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas.. 62. 2020
Safety and efficacy of navitoclax, a BCL-2 and BCL-X_L inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study.. 62. 2020
Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program.. 61. 2020
Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma.. 61. 2020
Poor graft function after T cell-depleted allogeneic hematopoietic stem cell transplant.. 61. 2020
Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816.. 61. 2020
Analysis of clinicopathological and cytogenetic differences between B-lymphoblastic lymphoma and B-lymphoblastic leukemia in childhood.. 61. 2020
Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients.. 61. 2020
Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia.. 61. 2020
The unique burden of rare cancer caregiving: caregivers of patients with Erdheim-Chester disease.. 61. 2020
Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey.. 61. 2020
Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia.. 61. 2019
HIV portends a poor prognosis in myelodysplastic syndromes.. 60. 2019
A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma.. 60. 2019
Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma.. 60. 2019
Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk.. 60. 2019
Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective.. 60. 2019
Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis.. 60. 2019
Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.. 60. 2018
Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.. 60. 2018
Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases.. 60. 2018
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.. 60. 2018
Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products.. 59. 2018
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.. 59. 2018
Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience.. 59. 2017
Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034.. 59. 2017
Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.. 59. 2017
CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.. 59. 2017
Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials.. 58. 2017
Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis - a retrospective study from a tertiary center.. 58. 2017
Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.. 58. 2017
Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant.. 58. 2017
Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).. 58. 2016
Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency.. 58. 2016
Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences.. 58. 2016
[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice.. 58. 2016
Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.. 58. 2016
Older patients with early-stage diffuse large B-cell lymphoma: the role of consolidation radiotherapy after chemoimmunotherapy.. 58. 2016
Clinicopathologic evaluation of cytopenic patients with isolated trisomy 8: a detailed comparison between idiopathic cytopenia of unknown significance and low-grade myelodysplastic syndrome.. 58. 2016
Short- and long-term outcomes of adult allogeneic hematopoietic stem cell transplant patients admitted to the intensive care unit in the peritransplant period.. 58. 2016
Cord blood chimerism and relapse after haplo-cord transplantation.. 58. 2016
Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population.. 57. 2016
Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma.. 57. 2016
Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging.. 57. 2016
Early human herpes virus type 6 reactivation in umbilical cord blood allogeneic stem cell transplantation.. 57. 2016
Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation.. 57. 2016
Impact of delays in definitive treatment on overall survival: a National Cancer Database study of patients with Hodgkin lymphoma.. 57. 2015
Early-stage nodular lymphocyte-predominant Hodgkin lymphoma: the impact of radiotherapy on overall survival.. 57. 2015
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.. 56. 2015
Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas.. 56. 2015
A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.. 56. 2015
Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma.. 56. 2015
Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.. 56. 2015
Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome.. 56. 2015
(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.. 56. 2014
Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method.. 56. 2014
Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant.. 56. 2014
Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.. 56. 2014
Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab.. 56. 2014
Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant.. 55. 2014
Sensitivity and specificity of cerebrospinal fluid flow cytometry for the diagnosis of leukemic meningitis in acute lymphoblastic leukemia/lymphoma.. 55. 2014
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.. 55. 2014
The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients.. 55. 2014
A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies.. 55. 2014
Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.. 55. 2014
Primary intraocular lymphoma: treatment outcomes with ocular radiation therapy alone.. 55. 2013
18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma.. 54. 2013
Immune reconstitution after combined haploidentical and umbilical cord blood transplant.. 54. 2013
Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database.. 54. 2013
Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia.. 54. 2013
The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance).. 54. 2013
Indolent non-Hodgkin lymphoma primarily involving the hard palate: outcome following radiotherapy.. 54. 2012
A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.. 54. 2012
Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies.. 54. 2012
Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?. 53. 2012
Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenström Macroglobulinemia 1.. 54. 2012
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma.. 53. 2012
Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.. 54. 2012
Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium.. 53. 2012
Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma.. 53. 2012
Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant.. 53. 2012
Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant.. 53. 2012
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).. 53. 2012
High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database.. 53. 2012
Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant.. 53. 2012
LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era.. 53. 2012
Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant.. 53. 2011
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.. 53. 2011
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.. 53. 2011
Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma.. 53. 2011
Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy.. 52. 2011
Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects.. 52. 2011
A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.. 52. 2011
T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse.. 52. 2010
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.. 51. 2010
Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy.. 51. 2010
How the microenvironment shapes chronic lymphocytic leukemia: the cytoskeleton connection.. 51. 2010
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.. 51. 2010
Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant.. 51. 2010
The antidepressants maprotiline and fluoxetine have potent selective antiproliferative effects against Burkitt lymphoma independently of the norepinephrine and serotonin transporters.. 51. 2010
A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia.. 51. 2010
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.. 50. 2009
Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial.. 50. 2009
Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma.. 50. 2009
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.. 50. 2009
Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphoma.. 49. 2008
FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma.. 49. 2008
Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma.. 49. 2008
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.. 49. 2008
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.. 48. 2007
Successful allogeneic transplantation of patients with suspected prior invasive mold infection.. 48. 2007
Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine.. 48. 2007
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.. 48. 2007
Incidence rates of the major leukemia subtypes among US Hispanics, Blacks, and non-Hispanic Whites.. 47. 2006
High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma.. 47. 2006
Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation?. 47. 2006
Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma.. 47. 2006
Venous thromboembolism in patients with diffuse large B-cell lymphoma.. 47. 2006
Expression of Akt (protein kinase B) and its isoforms in malignant lymphomas.. 46. 2005
R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy.. 46. 2005
High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma.. 45. 2004
Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression.. 44. 2003
BRCA1 and BRCA2 germline mutations in lymphoma patients.. 44. 2003
Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.. 44. 2003
Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia.. 43. 2002
Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children's Cancer Group.. 43. 2002
BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia.. 43. 2002
Analysis of mismatch repair defects in the familial occurrence of lymphoma and colorectal cancer.. 43. 2002
Extended survival in advanced-stage multiple myeloma patients treated with gallium nitrate.. 43. 2002
Impact of early response to sequential high-dose chemotherapy on outcome of patients with advanced myeloma and poor prognostic features.. 43. 2002
Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma.. 42. 2001
Experience with 9-cis retinoic acid in patients with relapsed and refractory non-Hodgkin's lymphoma.. 40. 2000
Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy.. 39. 2000
Phase II evaluation of a high-dose mitoxantrone based induction regimen in untreated adults with acute myeloid leukemia.. 38. 2000
Clinical significance of deletions of chromosome arm 6q in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group.. 36. 2000
Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma.. 35. 1999
Atypical BCR and ABL D-FISH patterns in chronic myeloid leukemia and their possible role in therapy.. 34. 1999
Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with secondary acute myelogenous leukemia in first remission.. 33. 1999
Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy.. 33. 1999
Prognostic significance of T-lineage leukemic cell growth in SCID mice: a Children's Cancer Group study.. 32. 1999
Familial Hodgkin's and non-Hodgkin's lymphoma: different patterns in first-degree relatives.. 27. 1997
Prognostic significance of the CD10+CD19+CD34+ B-progenitor immunophenotype in children with acute lymphoblastic leukemia: a report from the Children's Cancer Group.. 27. 1997
Expression of BCR-ABL, E2A-PBX1, and MLL-AF4 fusion transcripts in newly diagnosed children with acute lymphoblastic leukemia: a Children's Cancer Group initiative.. 26. 1997
Analysis of chimerism following allogeneic bone marrow transplantation by fluorescent-in-situ hybridization.. 25. 1997
Antimycotic therapy with liposomal amphotericin-B for patients undergoing bone marrow or peripheral blood stem cell transplantation.. 24. 1997
Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group Study.. 24. 1996
Interferon-inducible protein-10 and the pathogenesis of cutaneous T-cell lymphomas.. 24. 1996
Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies.. 23. 1996
Patterns of ganglioside expression in B cell neoplasms.. 21. 1996
BCL6 gene rearrangement and other cytogenetic abnormalities in diffuse large cell lymphoma.. 20. 1995
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma.. 17. 1995
Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemia.. 11 Suppl 2. 1993
Integration of molecular and biological abnormalities in quest for selective treatment of chronic myelogenous leukemia (CML).. 11 Suppl 2. 1993
Attempted prevention of blast crisis in chronic myeloid leukemia by the use of pulsed doses of cytarabine and lomustine. A Cancer and Leukemia Group B study.. 7. 1992
Alternatives in the Management of Gastric Lymphoma.. 4. 1991
Co-infection with HIV-I and HTLV-I/II In Intravenous Drug Users in Suburban New York City, With Comparison to Other Geographic Areas.. 3. 1991
Treatment of Philadelphia Chromosome Positive (Ph +) Chronic Myelogenous Leukemia in Blast Crisis and Ph + Acute Leukemia with High Dose Cytosine Arabinoside (HDARAC).. 4. 1991
Treatment Options for Hodgkin's Disease During Pregnancy.. 2. 1990
Mast cell sarcoma transdifferentiated from clonally-related T-lymphoblastic leukemia upon acquisition of TP53 mutation and genetic complexity. 2021
Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy.. 62. 2020
Evidence for separate transformation to acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm from a shared ancestral hematopoietic clone.. 61. 2020
Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy.. 61. 2020
A phase II clinical trial of lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while on lenalidomide maintenance: a tri-state transplant consortium study.. 61. 2020
Sequence matters: elotuzumab more effective if used before daratumumab.. 61. 2019
Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications.. 61. 2019
Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/BCR-FGFR1-rearranged myeloid/lymphoid neoplasm with RUNX1 mutation - diagnostic pitfalls and clinical management including FGFR1 inhibitor pemigatinib.. 61. 2019
Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia.. 60. 2019
The optimal chemotherapy regimen for primary mediastinal B-cell lymphoma: we may never know.. 60. 2019
Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma.. 60. 2019
Immunotherapy in mycosis fungoides: opening night or dress rehearsal?. 60. 2019
TPO-mimetics for chemotherapy-induced thrombocytopenia: timing matters.. 59. 2018
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.. 60. 2018
Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.. 59. 2017
Digging deeper in relapsed acute lymphoblastic leukemia: impact of MRD status on outcome in second remission.. 59. 2017
Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.. 59. 2017
Haploidentical hematopoietic stem cell transplantation with myeloablative conditioning regimen could serve as an optional salvage therapy for younger patients with refractory or relapsed aggressive non-Hodgkin lymphoma.. 58. 2017
Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance.. 58. 2017
Evaluation of serum erythropoietin values as defined by 2016 World Health Organization criteria for the diagnosis of polycythemia vera.. 58. 2017
Comparison of BCR/ABL1 mRNA levels by quantitative real-time PCR in peripheral blood and bone marrow specimens of patients with chronic myelogenous leukemia.. 58. 2017
Proteomic profiling in plasma cell disorders: a feasibility study.. 58. 2016
Frontline autologous stem cell transplant for high-risk follicular lymphoma: forever elusive?. 58. 2016
Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenström's macroglobulinemia.. 58. 2016
Not just leukemia: CMV may protect against lymphoma recurrence after allogeneic transplant.. 58. 2016
Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial.. 58. 2016
Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.. 58. 2016
Bendamustine and stem-cell mobilization: not so bad!. 57. 2016
Clonal plasma cells keep strange company.. 57. 2016
High-dose methotrexate-based chemotherapy as treatment for histiocytic sarcoma of the central nervous system.. 57. 2016
Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium.. 57. 2015
Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21).. 57. 2015
A translocation t(2;14)(p11.2;q32) involving rearrangements of immunoglobulin heavy chain and kappa light chain genes in B-cell lymphoma.. 56. 2015
Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.. 56. 2015
New frontiers for brentuximab vedotin for lymphomas.. 56. 2014
The hematocrit value in polycythemia vera: caveat utilitor.. 56. 2014
Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma.. 56. 2014
When indolent follicular lymphoma is not indolent.. 55. 2014
Statement of Retraction: Huang H, Wu D, Fu J, Chen G. "multiple myeloma cells undergo differentiation upon exposure to rosiglitazone and all-trans retinoic acid".. 55. 2014
Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma.. 55. 2013
Searching the central nervous system for relapsed acute promyelocytic leukemia.. 54. 2013
Bendamustine: a bridge to longer term solutions in heavily treated Hodgkin lymphoma.. 54. 2013
Analysis of prognostic factors for survival in 75 Chinese patients with peripheral T-cell lymphoma.. 55. 2013
Statement of retraction. Avilés A, Fernándezb R, Pérez F, Nambo MJ, Neri N, Talavera A, Castañeda C,González M, Cleto. Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome.. 54. 2013
FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status.. 54. 2013
Vascular endothelial growth factor expression in acute myeloid leukemia: a biomarker ready for primetime?. 54. 2013
Sustained remission in a patient with myelodysplastic syndrome and a complex karyotype after erythropoiesis-stimulating therapy followed by colonic T-cell lymphoblastic lymphoma.. 54. 2012
Limited-stage mantle cell lymphoma: not so different from advanced-stage.. 54. 2012
Refining the prognostic importance of the diversity of FLT3 internal tandem duplications.. 54. 2012
2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels.. 54. 2012
Primary follicular lymphoma of the gastrointestinal tract: effect of stage, symptoms and treatment choice on outcome.. 54. 2012
Does arsenic trioxide impact fertility?. 53. 2012
Chemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular liposomal cytarabine and high dose methotrexate for neurolymphomatosis.. 53. 2012
Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center.. 53. 2012
CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1: biomarkers in search of validation in lymphomas.. 53. 2012
Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression.. 53. 2011
Osteomalacia due to adult Fanconi syndrome in multiple myeloma.. 52. 2011
When 18-fluorodeoxyglucose-positron emission tomography is indeterminate, the International Prognostic Index is the answer.. 51. 2010
Is there a role for bone scan in Hodgkin lymphoma in the age of 18F-fluorodeoxyglucose positron emission tomography?. 50. 2009
Gastric Burkitt lymphoma associated with Efalizumab and Helicobacter pylori.. 50. 2009
Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings.. 48. 2007
Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: a randomized study caveat.. 48. 2007
Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestine.. 48. 2007
Possible role of edotecarin, a novel topoisomerase I inhibitor, in therapy-related myelodysplastic syndrome.. 48. 2007
The ABVD's of cooperative trials in pediatric Hodgkin lymphoma: The India experience. 2022
Allogeneic transplant graft source - conditioning - GVHD prophylaxis: don't mix and match! 2021
Measurable residual disease negativity in acute myeloid leukemia: the destination may matter more than the journey. 2021
Is less more? Viewpoint on empiric vancomycin therapy of fever and neutropenia after allogeneic stem cell transplantation. 2020
Allogeneic transplant for CML in chronic phase after failure of imatinib. Not needed or needlessly neglected? 2020
Busulfan or melphalan: is there a better conditioning regimen for allogeneneic transplantation? 2020
Combining haplo-identical and cord blood stem cell grafts - might the whole be greater than the sum of its parts? 2020
Donor graft genotypes versus leukemia. 2019
Tocilizumab, in search for a role in acute GVHD. 2019
It's not all about the CNS. High dose methotrexate in DLBCL. 2019
PET beyond Deauville in diffuse large B-cell lymphoma. 2019
Earlier may be better: the role of extracorporeal photopheresis (ECP) as prevention of GVHD after allogeneic transplant. 2017
Second allogeneic transplantation: ever? never? or sometimes. 2016
HLA: revisiting an old suspect in the complex pathogenesis of posttransplant lymphoproliferative disorders. 2016
Reducing radiation exposure in children with febrile neutropenia: can pulmonary MRI replace CT? 2015
A new "age" for high dose therapy and autologous stem cell transplant. 2015
EZH2: a potential new target in T-cell lymphoma? 2015
Great expectations? Conditioning with busulfan, melphalan and thiotepa in recurrent Hodgkin lymphoma. 2014
Pre-transplant serum ferritin is prognostic but is it useful? 2013
Therapeutic drug monitoring: a way to improve long-term immunological balance? 2012
Allogeneic transplant for peripheral T-cell lymphoma: a sparkle of hope and many questions. 2011
Advancing through maintenance in mantle cell lymphoma. 2011
Cord blood transplant: the glass is half full--can we do better? 2011
Influenza in patients with hematologic disease: an ounce of prevention is worth a pound of cure. 2010
Targeting angiogenesis: a novel, rational therapeutic approach for non-Hodgkin lymphoma. 2009
Late relapse following allogeneic transplant for chronic lymphocytic leukemia: how good are graft versus leukemia effects? 2008
IL-4 as therapy for non-Hodgkin's lymphoma: possibilities but major challenges. 2007
Toxicity of high dose BCNU: how much is too much? 2006
Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma. 2022
Excess mortality in younger patients with myeloproliferative neoplasms. 2022
Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. 2021
Use of eculizumab in autologous hematopoietic stem cell transplantation-associated thrombotic microangiopathy in two adults. 2021
A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib. 2021
Prognostic impact of serum CXC chemokine ligands 4 and 7 on myelodysplastic syndromes post allogeneic hematopoietic cell transplant. 2020
Impact of alemtuzumab dosing and low-dose total body irradiation on cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation. 2020
Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation. 2019
The application of precision medicine in diagnosing familial Mediterranean fever. 2019
A rare colonic manifestation of chronic lymphocytic leukemia. 2018
Cytogenetic analysis of adult T-Cell leukemia/lymphoma: evaluation of a Caribbean cohort. 2018
Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. 2018
Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia. 2017
The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data^. 2017
Haplo-cord transplant: HLA-matching determines graft dominance. 2016
Clofarabine as a bridge to hematopoietic stem cell transplant. 2016
Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant. 2016
Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor. 2016
Autologous stem cell transplant in human immunodeficiency virus-positive patients with lymphoid malignancies: focus on infectious complications. 2012
Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. 2011
Monomorphic T-cell post-transplant lymphoproliferative disorders exhibit markedly inferior outcomes compared to monomorphic B-cell post-transplant lymphoproliferative disorders. 2010
Fourth complete remission with immunosuppression withdrawal and irinotecan after both autologous and allogeneic transplants for diffuse large B cell lymphoma. 2009
Cardiac tamponade in a patient with chronic lymphocytic leukemia. 2007
Interdigitating dendritic cell tumors in two patients exposed to topical calcineurin inhibitors. 2007
Mantle cell lymphoma: report of the 2009 Mantle Cell Lymphoma Consortium Workshop. 2010
Happy anniversary to the 10th ICML--International Conference on Malignant Lymphoma in Lugano, 4-7 June 2008With a personal tribute to the conference president and founder of ICML--Professor Franco Cavalli.. 49. 2008
Therapy for older patients with diffuse large cell lymphoma: targeting the treatment to the patient.. 48. 2007
Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications. 2019
Differentiating factors in treatment-free remission trials: impact of study design on results and clinical applications. 2018
Enhancer of zeste homolog 2 (EZH2) inhibitors. 2018
CAR T cell therapy for multiple myeloma: where are we now and where are we headed? 2017
Targeting histone deacetylases in T-cell lymphoma. 2016
The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies. 2016
Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. 2016
Management of adverse events associated with idelalisib treatment: expert panel opinion. 2015
Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. 2014
The prognostic impact of peripheral blood progenitor cell dose following high-dose therapy and autologous stem cell transplant for hematologic malignancies. 2014
The role of radiation therapy in the management of primary central nervous system lymphoma. 2014
PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas. 2014
Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia. 2014
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. 2014
The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma. 2014
Indolent mantle cell lymphoma. 2013
Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. 2012
Evolving therapeutic paradigms for multiple myeloma: back to the future. 2012
Current and future imaging modalities for multiple myeloma and its precursor states. 2011
Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma. 2010
Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas. 2008
Hematopoiesis and retinoids: development and disease. 2003
CD40 ligand in CLL pathogenesis and therapy. 2000
Regulation of hematopoiesis by microvascular endothelium. 1997
Haplo-cord transplant. Realizing the potential of umbilical cord blood grafts. - A review of techniques and analysis of outcomes. 2024
Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond. 2023
Hematological manifestations of COVID-19. 2020
An update on options of therapy for aggressive mantle cell lymphoma. 2020
Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics. 2019
Myasthenia gravis, an autoimmune manifestation of lymphoma and lymphoproliferative disorders: case reports and review of literature. 2011
Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. 2010
Advances in mobilization for the optimization of autologous stem cell transplantation. 2009
Ubiquitin ligases in malignant lymphoma. 2004
Dendritic cell-based immunotherapy in multiple myeloma. 2003
Interleukin-12 gene therapy vaccines: directing the immune system against minimal residual leukemia. 2001

VIVO Weill Cornell Medical College

Leukemia & lymphoma Journal

Overview

publication venue for

contributor

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)